Paper
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme
Published 2022 · S. Mead, A. Khalili-Shirazi, Caroline Potter
0
Citations
0
Influential Citations
Abstract
MRC Prion Unit at UCL, UCL Institute of Prion Diseases (Prof S Mead FRCP, A Khalili-Shirazi PhD, C Potter PhD, T Mok MRCP, A Nihat MRCP, S Canning BSc, C Schmidt BSc, T Campbell BSc, L Darwent MSc, N Muirhead PhD, N Ebsworth PhD, P Hextall BSc, M Wakeling PhD, J Linehan BSc, Prof S Brandner FRCPath, P Rudge FRCP, Prof J Collinge FRS), Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology (Z Jaunmuktane FRCPath), and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology (Prof S Brandner), University College London, London, UK; National Prion Clinic (Prof S Mead, A Khalili-Shirazi, T Mok, A Nihat, P Rudge, Prof J Collinge), Department of Neuroradiology (H Hyare FRCR), and Division of Neuropathology (Z Jaunmuktane, Prof S Brandner), National Hospital for Neurology and Neurosurgery, London, UK; NIHR, Biomedical Research Centre (Prof V Libri FRCP, Prof B Williams FMedSci) and Clinical Research Facility (Prof V Libri FRCP), University College London Hospitals, London, UK
PRN100 therapy shows potential as a first-in-human treatment for Creutzfeldt-Jakob disease, a fatal neurodegenerative disorder.
Full text analysis coming soon...